Evidence map›Paper›PMID 32252299›Full record

ArticleCancers2020

Comparative Analysis of Urine Fractions for Optimal Bladder Cancer Detection Using DNA Methylation Markers.

Anouk E Hentschel, Jakko A Nieuwenhuijzen, Judith Bosschieter, Annina P van Splunter, Birgit I Lissenberg-Witte, J Patrick van der Voorn, Loes I Segerink, R Jeroen A van Moorselaar, Renske D M Steenbergen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Urinary Markers for Bladder Cancer Diagnosis and Monitoring.Frontiers in cell and developmental biology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Anouk E HentschelUrology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1118, 1182 DB Amsterdam, The Netherlands.
Jakko A NieuwenhuijzenUrology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1118, 1182 DB Amsterdam, The Netherlands.
Judith BosschieterUrology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1118, 1182 DB Amsterdam, The Netherlands.
Annina P van SplunterPathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1118, 1182 DB Amsterdam, The Netherlands.
Birgit I Lissenberg-WitteEpidemiology & Biostatistics, Amsterdam Public Health, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
J Patrick van der VoornPathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1118, 1182 DB Amsterdam, The Netherlands.
Loes I SegerinkBIOS Lab on a Chip group, MESA+ institute for Nanotechnology, Technical Medical Centre, University of Twente, Hallenweg 15, 7522 NH Enschede, The Netherlands.ORCID 0000-0001-6943-8156
R Jeroen A van MoorselaarUrology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1118, 1182 DB Amsterdam, The Netherlands.
Renske D M SteenbergenPathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1118, 1182 DB Amsterdam, The Netherlands.ORCID 0000-0002-2327-9839
Amsterdam University Medical Centers · NLUniversity of Twente · NL

Funding

Stichting De Weijerhorst Funding other than grand
6 · The paper itself

Abstract

DNA methylation analysis of full void urine and urine pellet seems promising for bladder cancer (BC) detection and surveillance. Urinary cell-free DNA from urine supernatant is now gaining interest for other molecular tests in BC. This study aims to evaluate which urine fraction is preferred for BC diagnosis using methylation markers: full void urine, urine pellet or supernatant. Methylation levels of nine markers were determined in the three urine fractions and correlated with their respective tumor tissues in BC patients and compared to controls. For all markers and marker panel

Indexed as

biomarkersmethylationmolecular diagnosticsurinary bladder neoplasmsurine analysis

Identifiers

PMID32252299
PMCPMC7226114
OpenAlexW3014802889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.